Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 26, 2017
What is the competitive landscape for LILLY, and what generic alternatives to LILLY drugs are available?
LILLY has one hundred and thirty approved drugs.| Patents: | 26 |
| Tradenames: | 119 |
| Ingredients: | 102 |
| NDAs: | 130 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
pemetrexed disodium | For Injection | 750 mg/vial | ALIMTA | 10/6/2016 |
teriparatide | Injection | 250 mcg/mL, 2.4 mL prefilled Pen | FORTEO | 7/27/2015 |
pemetrexed disodium | For Injection | 1000 mg/vial | ALIMTA | 6/27/2012 |
duloxetine hydrochloride | Delayed-release Capsules | 40 mg | CYMBALTA | 5/10/2012 |
tadalafil | Tablets | 2.5 mg | CIALIS | 10/14/2008 |
duloxetine hydrochloride | Delayed-release Capsules | 20 mg, 30 mg and 60 mg | CYMBALTA | 8/4/2008 |
pemetrexed disodium | For Injection | 100 mg/vial | ALIMTA | 7/1/2008 |
olanzapine and fluoxetine hydrochloride | Capsules | 3 mg/25 mg | SYMBYAX | 5/8/2008 |
pemetrexed disodium | For Injection | 500 mg/vial | ALIMTA | 2/4/2008 |
tadalafil | Tablets | 5 mg, 10 mg and 20 mg | CIALIS | 11/21/2007 |
gemcitabine | For Injection | 2 g/vial | GEMZAR | 8/24/2007 |
atomoxetine hydrochloride | Capsules | 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg | STRATTERA | 5/29/2007 |
gemcitabine | For Injection | 1g/vial | GEMZAR | 11/14/2005 |
gemcitabine | For Injection | 200 mg/vial | GEMZAR | 11/1/2005 |
olanzapine and fluoxetine hydrochloride | Capsules | 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg | SYMBYAX | 1/10/2005 |
| Patent Number | Expiration Date |
|---|---|
| ► Subscribe | ► Subscribe |
| ► Subscribe | ► Subscribe |
| ► Subscribe | ► Subscribe |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7,857,791 | Medication dispensing apparatus with gear set having drive member accommodating opening | ► Subscribe | |||||||||||||
| 4,996,206 | N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives | ► Subscribe | |||||||||||||
| 6,369,059 | Tetracyclic derivatives, process of preparation and use | ► Subscribe | |||||||||||||
| 6,608,065 | Use of cGMP phosphodiesterase inhibitors in methods to treat female sexual dysfunction | ► Subscribe | |||||||||||||
| 6,143,746 | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use | ► Subscribe | |||||||||||||
| 5,981,527 | Cyclic GMP-specific phosphodiesterase inhibitors | ► Subscribe | |||||||||||||
| 6,841,167 | .beta.-carboline pharmaceutical compositions | ► Subscribe | |||||||||||||
| 5,248,775 | Pyrrolo(2,3-d)pyrimidines | ► Subscribe | |||||||||||||
| 6,025,494 | Tetracyclic derivatives, process of preparation and use | ► Subscribe | |||||||||||||
| 7,427,275 | Medication dispensing apparatus with triple screw threads for mechanical advantage | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Canada | 2031890 | ► Subscribe | |||||||||||||
| Colombia | 5170493 | ► Subscribe | |||||||||||||
| European Patent Office | 1656170 | ► Subscribe | |||||||||||||
| South Korea | 100357411 | ► Subscribe | |||||||||||||
| Peru | 75399 | ► Subscribe | |||||||||||||
| Czech Republic | 9800032 | ► Subscribe | |||||||||||||
| Slovakia | 94096 | ► Subscribe | |||||||||||||
| Australia | 4490900 | ► Subscribe | |||||||||||||
| African Regional IP Organization (ARIPO) | 556 | ► Subscribe | |||||||||||||
| Argentina | 033639 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C/GB95/010 | United Kingdom | ► Subscribe | PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215 | ||||||||||||
| 2209800/01 | Switzerland | ► Subscribe | PRODUCT NAME: INSULIN DEGLUDEC + LIRAGLUTIDE; REGISTRATION NO/DATE: SWISSMEDIC 65041 12.09.2014 | ||||||||||||
| 00021 | Netherlands | ► Subscribe | PRODUCT NAME: INSULINE ASPART EN GEKRISTALLISEERD PROTAMINE-INSULINE ASPART; NAT. REGISTRATION NO/DATE: EU/1/00/142/001 20000801; FIRST REGISTRATION: 55414015541502 2000230623 | ||||||||||||
| 13/055 | Ireland | ► Subscribe | PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624 | ||||||||||||
| C0020 | France | ► Subscribe | PRODUCT NAME: INSULIN DETEMIR; NAT. REGISTRATION NO/DATE: EU/1/04/278/001 20040601; FIRST REGISTRATION: LI - 56370 20031110 | ||||||||||||
| 0722 | Netherlands | ► Subscribe | PRODUCT NAME: TOBRAMYCINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: C(2011)5394 20110720 | ||||||||||||
| /2000 | Austria | ► Subscribe | PRODUCT NAME: INSULIN ASPART/PROTAMIN; NAT. REGISTRATION NO/DATE: EU/1/00/142/001-008 20000801; FIRST REGISTRATION: LI 55414-55416 20000623 | ||||||||||||
| 2013000061 | Germany | ► Subscribe | PRODUCT NAME: INSULIN DEGLUDEC IN ALLEN DURCH DAS BASISPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/12/807/001 EU/1/12/807/004-005 EU/1/12/807/007-009 EU/1/12/807/012-013 EU/1/12/807/015 20130121 | ||||||||||||
| 147 | Luxembourg | ► Subscribe | 91147, EXPIRES: 20151210 | ||||||||||||
| 00125 | Netherlands | ► Subscribe | PRODUCT NAME: ROSUVASTATINUM, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET CALCIUMZOUT; REGISTRATION NO/DATE: RVG 26872 - RVG 26874 20021106 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,766 others who get our Drug Patent Expiration Alerts:
